Latest BioLife Solutions Inc. Stories
10% Dextran 40 in 0.9% NaCl or 5% Dextrose Packaged in Bulk Bag Containers for Cell Preparation BOTHELL, Wash., Feb.
Proprietary Products Revenue Growth of 25% over 2013; HypoThermosol® and CryoStor® Now Embedded in 175 Regenerative Medicine Clinical Trials BOTHELL, Wash., Jan.
Proprietary, Clinical Grade HypoThermosol® and CryoStor® Extending Shelf Life and Improving Survival & Function of CAR-T Cells, Dendritic Cells, Etc. BOTHELL, Wash., Jan.
BOTHELL, Wash., Dec. 24, 2014 /PRNewswire/ -- BioLife Solutions, Inc.
Key Executive Will Support Adoption of biologistex(SM) Cold Chain Management Service and EVO(TM) Smart Containers for Temperature Sensitive Biologics BOTHELL, Wash., Dec.
BOTHELL, Wash., Nov. 25, 2014 /PRNewswire/ -- BioLife Solutions, Inc.
Single-Use Syringes and Bulk Dispensing Bags with Sterile Dockable Tubing Offer Improved Aseptic Processing of Clinical Cells and Tissues BOTHELL, Wash., Nov.
BOTHELL, Wash., Oct. 30, 2014 /PRNewswire/ -- BioLife Solutions, Inc.
Adult Mesenchymal Stem Cells Demonstrate Enhanced Survival and Recovery Following Cryopreservation with CryoStor, Reducing Research Costs and Expansion Time BOTHELL, Wash., Oct.
HypoThermosol® and CryoStor® Embedded in Internal Cell Therapy Candidates and Numerous Mutual Customer Regenerative Medicine Applications BOTHELL, Wash., Oct.
- A political dynamiter.